BioNTech

• Initial Public Offering on the Nasdaq Global Select Market of 10,000,000 American Depositary Shares (“ADSs”) at a price of USD 15.00 per ADS, raising a total of USD 150 million
• In addition, the company granted the underwriters a 30-day option to purchase up to 1,500,000 additional ADSs, which could result in the gross proceeds to grow to USD 172.5 million in case the over-allotment option is exercised in full
• The transaction represents the largest primary NASDAQ biotech IPO in terms of valuation of 2019 to date, as well as the largest primary IPO of any German biotech
  Recognised for its Life Sciences sector knowledge and deep specialist investor inroads, Kempen was selected to assist the Germany biotechnology company with its outreach towards European and Israeli, as well as US investors
• BioNTech’s IPO marks the third Initial Public Offering on an American stock exchange in which Kempen acted as an underwriter in 2019

BioNTech was founded in 2008 on the understanding that every cancer patient’s tumour is unique and therefore each patient’s treatment should be individualised. Its cutting-edge pipeline includes individualised mRNA-based product candidates, innovative chimeric antigen receptor T cells, novel checkpoint immunomodulators, targeted cancer antibodies and small molecules. BioNTech has established relationships with seven pharmaceutical collaborators, including Eli Lilly and Company, Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant and Pfizer, and has published over 150 peer-reviewed publications on its scientific approach.